Q-omics provides the consensus-scored DHH profile across patient tissues and cancer cell-line models. DHH expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DHH is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, DHH RNA expression shows 13,945 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight KIRC, KICH, and CCRCC as cancer lineages where DHH shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DHH — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DHH survival associations across molecular data types. DHH RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DHH RNA expression–survival associations across cancer types. High DHH expression shows unfavorable associations in MESO, LGG and KIRP, but favorable associations in KIRC, SARC and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DHH RNA expression.
This table summarizes DHH tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for DHH. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DHH shows lower tumor expression in KICH, KIRP, KIRC, BLCA and LUAD and higher tumor expression in LIHC. The KICH box plot shows higher DHH RNA expression in normal versus tumor tissue (log2 FC = −1.457, t-test p < 0.001).
This table shows molecular features associated with DHH in patient tissues and cancer cell lines. In patient samples, DHH shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, DHH RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
